🆕| Oxford University begins HIV vaccine trial A Phase I trial began today to evaluate the safety, tolerability, & immunogenicity of the HIVconsvX vaccine. It targets a broad range of HIV-1 variants - so it could have an effect on HIV strains in any geographical region. More info ⬇️ https://bit.ly/2VbeS4Y | University of Oxford

Oxford University’s Professor Andrew Pollard explains the process behind creating a vaccine. University of Oxford | UK Prime Minister

The Oxford coronavirus vaccine has been shown to trigger a robust immune response in healthy adults aged 56-69 and 70 . The data suggest that one of the groups most vulnerable to serious illness and death from COVID-19 could build immunity: https://bit.ly/2IOWGIx #OxfordVaccine | University of Oxford

BREAKING: Results from phase one of trials of a #COVID19 vaccine being developed at the University of Oxford, show it induces an immune reaction. Sky's Sadiya Chowdhury has the latest. Find out more here: https://trib.al/C7RzS4l | Sky News

92K views · 1.2K reactions | "It’s an incredible thing to be part of a study that will hopefully develop a vaccine." Hear from Dr Maheshi Ramasamy about her work on the clinical trials for the Oxford #COVID19 vaccine. Watch  University of Oxford | Oxford Vaccine Group, Department of Paediatrics, University of Oxford | Jenner Institute Vaccine Trials, University of Oxford | Department of Health and Social Care - DHSC | Facebook

Oxford vaccine trials have shown good early results. Phase 1 and 2 of the trials have shown that the vaccine prompts a protective immune response in people and that candidates are safe and well- tolerated. The vaccine has also not shown any adverse effects so far. Reports are now suggesting that an Astra Zeneca-backed vaccine may be out by September. | News18